Takeda Pharmaceutical Co. Ltd. Makes New $564,000 Investment in American Well Co. (NYSE:AMWL)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of American Well Co. (NYSE:AMWL) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 77,733 shares of the company’s stock, valued at approximately $564,000. American Well comprises about 2.1% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 6th biggest holding.

Other large investors have also recently modified their holdings of the company. Compagnie Lombard Odier SCmA bought a new stake in American Well in the 4th quarter worth $45,000. BNP Paribas Financial Markets purchased a new stake in shares of American Well during the third quarter worth about $95,000. PDT Partners LLC purchased a new position in American Well during the 3rd quarter valued at about $107,000. Walleye Capital LLC purchased a new position in American Well during the 3rd quarter valued at about $167,000. Finally, HighTower Advisors LLC bought a new position in American Well during the 3rd quarter valued at approximately $355,000. Hedge funds and other institutional investors own 56.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AMWL. Truist Financial lifted their price objective on American Well from $10.00 to $12.00 and gave the stock a “hold” rating in a research report on Friday, February 14th. Wells Fargo & Company upgraded shares of American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 price objective for the company in a report on Monday, January 13th. Morgan Stanley cut their target price on shares of American Well from $20.00 to $10.50 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of American Well in a research note on Thursday, February 13th. Finally, Stifel Nicolaus lifted their price objective on American Well from $9.00 to $10.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, American Well presently has a consensus rating of “Hold” and a consensus price target of $11.90.

American Well Price Performance

Shares of American Well stock opened at $7.93 on Thursday. American Well Co. has a 1 year low of $5.00 and a 1 year high of $17.54. The company has a 50-day moving average of $9.99 and a 200 day moving average of $9.31. The firm has a market cap of $123.82 million, a price-to-earnings ratio of -0.57 and a beta of 1.18.

American Well (NYSE:AMWL) last released its earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.04) by $0.27. American Well had a negative net margin of 81.83% and a negative return on equity of 56.73%. On average, equities analysts anticipate that American Well Co. will post -9.34 EPS for the current year.

Insiders Place Their Bets

In other news, insider Phyllis Gotlib sold 4,781 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.80, for a total transaction of $42,072.80. Following the completion of the transaction, the insider now directly owns 147,998 shares in the company, valued at $1,302,382.40. This trade represents a 3.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 5,219 shares of company stock valued at $46,454. 12.80% of the stock is currently owned by corporate insiders.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.